## TAPPAHANNOCK HOSPITAL ANTIBIOTIC SUSCEPTIBILITY TABLES JANUARY – DECEMBER 2022

## Department of Pathology - Microbiology/Immunology

Table 1. Activity of selected antibiotics against gram-positive cocci

| Percentage (%) of Organisms Susceptible |               |            |                        |            |              |             |         |               |                           |           |
|-----------------------------------------|---------------|------------|------------------------|------------|--------------|-------------|---------|---------------|---------------------------|-----------|
| Organism                                | Number Tested | Ampicillin | Oxacillin <sup>a</sup> | Vancomycin | Tetracycline | Clindamycin | TMP/SMX | Ceftaroline ° | Daptomycin <sup>b.c</sup> | Linezolid |
| Staphylococcus aureus                   | 58            |            | 65                     | 100        | 89           | 80          | 100     | 100           | 100                       | 100       |
| Enterococcus faecalis                   | 51            | 100        |                        | 100        |              |             |         |               | 91                        | 100       |

a Staphylococci resistant to oxacillin (methicillin) are also resistant to penicillin, ampicillin, cefazolin, cefoxitin, ceftriaxone, meropenem and all other beta-lactam antibiotics. Staphylococci species breakpoints are in use.

Table 2. Activity of selected antibiotics against gram-negative bacilli

| Table 2. Activity of Selected antibiotics against grant-negative bacini |                  |            |            |           |          |             |           |            |               |                 |         |                |
|-------------------------------------------------------------------------|------------------|------------|------------|-----------|----------|-------------|-----------|------------|---------------|-----------------|---------|----------------|
| Percentage (%) of Organisms Susceptible                                 |                  |            |            |           |          |             |           |            |               |                 |         |                |
| Organism                                                                | Number<br>Tested | Ampicillin | Pip/Tazo º | Cefazolin | Cefepime | Ceftriaxone | Meropenem | Gentamicin | Ciprofloxacin | Levofloxacin    | TMP/SMX | Nitrofurantoin |
| Escherichia coli                                                        | 342              |            | 99         | 89        | 96       | 93          | 100       | 92         | 78            | 81              | 82      | 97             |
| Klebsiella pneumoniae                                                   | 72               | IR         | 97         | 90        | 91       | 91          | 100       | 95         | 90            | 95              | 86      |                |
| Proteus mirabilis <sup>a</sup>                                          | 56               | 92         | 100        | 90        | 98       | 98          | 100       | 94         | 81            | 83              | 82      |                |
| Pseudomonas aeruginosa                                                  | 37               | IR         | 97         |           | 100      | IR          | 97        | 97         | 83            | 70 <sup>b</sup> | IR      |                |

IR = Intrinsic Resistance

Data collected by the Clinical Microbiology Laboratory, Department of Pathology CLSI M100-ed32 and M60-ed2 Interpretation breakpoints were applied unless otherwise stated.

<sup>&</sup>lt;sup>b</sup> Respiratory tract isolates included in Daptomycin results though excluded from reporting per CLSI M100 guidelines.

<sup>&</sup>lt;sup>c</sup> Ceftaroline and Daptomycin results include Susceptible Dose Dependent (SDD) isolates.

<sup>&</sup>lt;sup>a</sup> Proteus species other than Proteus mirabilis are more resistant (similar to Morganella species).

<sup>&</sup>lt;sup>b</sup> Levofloxacin breakpoints for Pseudomonas aeruginosa are based on a dosage regimen of 750mg every 24 hours.

<sup>&</sup>lt;sup>c</sup> Piperacillin/tazobactam and Cefepime results include Susceptible Dose Dependent (SDD) isolates.